GLUE
Monte Rosa Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.13
−3.73%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.23
- Revenue estimate
- $31.1M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.43
- EPS estimate
- -$0.38
- Revenue actual
- $9.0M
- Revenue estimate
- $12.6M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -28.0%
- Revenue beats (12Q)
- 6
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $27
- PT range
- $27 – $28
- Analysts
- 4
4 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.38 | -$0.43 | Miss -13.02% | $9.0M |
| May 7, 2026 | -$0.28 | -$0.45 | Miss -60.71% | $4.2M |
| Mar 17, 2026 | -$0.35 | -$0.54 | Miss -53.61% | $2.8M |
| Nov 6, 2025 | -$0.39 | -$0.33 | Beat 15.38% | $12.8M |
| Aug 7, 2025 | -$0.31 | -$0.15 | Beat 51.61% | $23.2M |
| May 8, 2025 | -$0.24 | $0.57 | Beat 337.50% | $84.9M |
| Mar 20, 2025 | -$0.37 | $0.23 | Beat 162.16% | $60.6M |
| Nov 7, 2024 | -$0.45 | -$0.29 | Beat 35.56% | $9.2M |
| Aug 8, 2024 | -$0.50 | -$0.43 | Beat 14.00% | $4.7M |
| May 9, 2024 | -$0.56 | -$0.53 | Beat 5.36% | $1.1M |
| Mar 14, 2024 | -$0.57 | -$0.58 | Miss -1.75% | $8.8M |
| Nov 9, 2023 | -$0.75 | -$0.70 | Beat 6.67% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026